Literature DB >> 7874885

Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.

R N Jones1.   

Abstract

CP-99219 is a novel 7-[3-azabicyclo (3.1.0) hexyl] quinolone that possesses activity against a wide variety of aerobic and anaerobic pathogens. The disk diffusion test results (5-micrograms CP-99219 disks) were compared with CP-99219 minimum inhibitory concentrations (MICs) using 445 contemporary clinical isolates, including 210 strains that were resistant to ciprofloxacin (MICs, > or = 4 micrograms/ml). A high correlation was observed between methods (r = 0.97), and the proposed conservative zone diameter interpretive criteria were selected primarily from the regression equation as follows: susceptible at > or = 15 mm (< or = 2 micrograms/ml, preferred) and resistant at < or = 10 mm (> or = 8 micrograms/ml); or susceptible at > or = 19 mm (< or = 1 microgram/ml) and resistant at < or = 14 mm (> or = 4 micrograms/ml). Using these criteria, the occurrence of false-resistant and false-susceptible disk diffusion test results should remain rare (< or = 1.5%).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7874885     DOI: 10.1016/0732-8893(94)90112-0

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Community-acquired Acinetobacter baumannii bacteremia in adult patients in Taiwan.

Authors:  Jann-Tay Wang; Lawrence Clifford McDonald; Shan-Chwen Chang; Monto Ho
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.

Authors:  P C Fuchs; A L Barry; S D Brown; D L Sewell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

4.  Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.

Authors:  D T Dubin; J E Fitzgibbon; M D Nahvi; J F John
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.

Authors:  J E Fitzgibbon; J F John; J L Delucia; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.

Authors:  S P Murphy; M G Cormican; R N Jones
Journal:  Ir J Med Sci       Date:  1995 Oct-Dec       Impact factor: 1.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.